National Institutes of Health: Acute Lung Injury trials

The registry lists 13 Acute Lung Injury studies with National Institutes of Health as lead sponsor. 2 are open to participants now and 3 have results posted.

Phase 1 2Phase 2 3Phase 3 9(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Fibrotic Disease Activity in Cardiopulmonary Disorders Using 18F-Fibroblast Activation Protein Inhibitor (18F-FAPI-74) PET/CT ImagingRecruitingNCT07613099Phase 3
• Belumosudil to Block Chronic Lung Allograft Dysfunction (CLAD) in High Risk Lung Transplant RecipientsRecruitingNCT06476132Phase 2
• Tocilizumab for Patients With Cancer and COVID-19 DiseaseTerminatedNCT04370834Phase 2Results posted
• Statins for Acutely Injured Lungs From SepsisTerminatedNCT00979121Phase 3Results posted
• Drug Study of Albuterol to Treat Acute Lung InjuryTerminatedNCT00434993Phase 2/3Results posted
• Early Versus Delayed Enteral Feeding to Treat People With Acute Lung Injury or Acute Respiratory Distress Syndrome (The EDEN Study)CompletedNCT00883948Phase 3
• Poly-ICLC to Prevent Respiratory Viral Infections A Safety StudyCompletedNCT00646152Phase 1
• Early Versus Delayed Enteral Feeding and Omega-3 Fatty Acid/Antioxidant Supplementation for Treating People With Acute Lung Injury or Acute Respiratory Distress Syndrome (The EDEN-Omega Study)TerminatedNCT00609180Phase 3
• Corticosteroids as Rescue Therapy for the Late Phase of Acute Respiratory Distress SyndromeCompletedNCT00295269Phase 3
• Fluids and Catheters Treatment Trial (FACTT) - ARDS Clinical Research NetworkCompletedNCT00281268Phase 3
• Prone Positioning in Pediatric Acute Lung InjuryCompletedNCT00133614Phase 3
• Carbon Monoxide to Prevent Lung InflammationCompletedNCT00094406Phase 1
• Acute Respiratory Distress Syndrome Clinical Network (ARDSNet)CompletedNCT00000579Phase 3